MTVA MetaVia Inc.
Price Chart
Executive Summary
MetaVia reported Q1 2026 net loss of $3.8M ($0.79/share) vs $3.7M ($3.93/share) in Q1 2025, with cash of $13.7M expected to fund operations into Q4 2026. The key catalyst is the ongoing Phase 1 Part 3 titration study of DA-1726 (obesity), with first patient dosed in April and data expected in Q4 2026. The filing is a routine quarterly update for a clinical-stage biotech with no new clinical data or financial surprises.
Actionable Insight
No new clinical data or financial surprises — the stock will trade on DA-1726 Phase 1 Part 3 data expectations, not Q1 results. Monitor for Q4 2026 data readout and any partnership announcements for vanoglipel. The $13.7M cash runway into Q4 2026 means a dilutive financing is likely needed before year-end if no partnership materializes.
Key Facts
- Net loss of $3.8M ($0.79/share) for Q1 2026 vs $3.7M ($3.93/share) in Q1 2025
- Cash and cash equivalents of $13.7M as of March 31, 2026, up from $10.2M at year-end 2025
- First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726 (obesity) in April 2026
- Phase 1 Part 3 data readout for DA-1726 expected in Q4 2026
- R&D expenses were $2.1M in Q1 2026 vs $2.3M in Q1 2025
- Weighted average shares outstanding increased to 4,859,567 from 933,109 year-over-year due to January 2026 public offering
- Company expects cash to fund operations into Q4 2026
Financial Impact
Net loss of $3.8M in Q1 2026, essentially flat vs $3.7M in Q1 2025. Cash burn rate remains low at ~$1.3M/month. No revenue reported.
Risk Factors
- Cash runway only into Q4 2026 — likely need for additional dilutive financing
- DA-1726 Phase 1 Part 3 data is binary and not expected until Q4 2026
- Massive dilution from January 2026 offering (shares outstanding increased 5.5x year-over-year)
- No revenue and pre-commercial stage with high clinical development risk
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-061148 |
| Document: mtva-20260514xex99d2.htm | 0001104659-26-061148 |
| Document: mtva-20260514x8k.htm | 0001104659-26-061148 |
| Document: 0001104659-26-061148-index-headers.html | 0001104659-26-061148 |
| Document: 0001104659-26-061148-index.html | 0001104659-26-061148 |
| Document: 0001104659-26-061148.txt | 0001104659-26-061148 |
| 8-K Data (Synthetic) | 0001104659-26-061148 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
8-K
| $2.22 awaiting T+5 | awaiting T+5 | — | $1.74 (−21.62%) |
|
Jun 8, 2026
4d ago
|
8-K
| $2.22 awaiting T+5 | awaiting T+5 | — | $1.74 (−21.62%) |
|
May 27, 2026
16d ago
|
8-K
| $3.34 $2.71 | ▼ −18.86% | ▼ −20.07% | $1.74 (−47.90%) |
|
May 18, 2026
25d ago
|
8-K
| $1.11 $2.97 | ▲ +167.57% | ▲ +165.95% | $1.74 (+56.76%) |
|
May 14, 2026
29d ago
|
8-K
| $1.11 $3.85 | ▲ +246.85% | ▲ +245.88% | $1.74 (+56.76%) |
|
Apr 10, 2026
9w ago
|
8-K
| $1.41 $1.40 | ▼ −0.71% | ▼ −5.21% | $1.74 (+23.40%) |
|
Apr 7, 2026
9w ago
|
EFFECT
| $1.21 $1.49 | ▲ +23.14% | ▲ +17.81% | $1.74 (+43.80%) |
|
Mar 18, 2026
12w ago
|
8-K
| $1.48 $1.30 | ▼ −12.16% | ▼ −11.45% | $1.74 (+17.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access